---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-25-000009"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:57:16.015315+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q4 2024 net loss $18.7M; advances SL-325 DR3 antibody to Phase 1

## Summary
- Cash and investments $73.0M as of Dec 31, 2024; expected to fund operations into 2027.
- Net loss Q4 2024 $18.7M ($0.37/share) vs $17.7M ($0.41) Q4 2023; FY loss $75.4M vs $87.3M.
- R&D expenses $15.4M Q4; full year $67.2M down from $74.3M due to termination of SL-172154 program.
- SL-325 DR3 blocking antibody on track for IND filing in Q3 2025; Phase 1 enrollment expected complete Q2 2026.
- Preclinical NHP data at ECCO showed favorable safety, full receptor occupancy, no DR3 agonism.

## SEC filing metadata
- accession: 0001680367-25-000009
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036725000009/0001680367-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036725000009/sttk-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-25-000009
- JSON: https://secwatch.observer/filing/0001680367-25-000009.json
- Plain text: https://secwatch.observer/filing/0001680367-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.